QINLOCK
As listed in the register: QINLOCK
50 mg · tablet
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Ripretinib
- Made by
- Deciphera Pharmaceuticals. Llc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (QINLOCK). It describes the substance, not this exact product.
Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, and secondary mutations.
Ripretinib also inhibits other kinases in vitro, such as PDGFRB, TIE2, VEGFR2, and BRAF.
No clinically significant differences in the C max and AUC 0-24h were observed between administration of QINLOCK with a high-fat meal (150, 250, and 500-600 calories from protein, carbohydrate, and fat, respectively) and under fasted conditions.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-05-12
Safety of the active substance
From the US prescribing label for the same active substance (QINLOCK). It describes the substance, not this exact product.
The most common Grade 3 or 4 laboratory abnormalities (≥4%) were increased lipase and decreased phosphate.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Deciphera Pharmaceuticals. Llc |
|---|---|
| Active substance | Ripretinib |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 50 mg |
| Form | tablet |
| Classification | L01EX19 · Cancer treatments and immune-system medicines |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02500833 |
| DPD drug code | 99049 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.